RT Journal Article
T1 Multivalent antibodies: when design surpasses evolution
A1 Cuesta Martínez, Ángel
A1 Sainz-Pastor, Noelia
A1 Bonet, Jaume
A1 Oliva, Baldomero
A1 Álvarez-Vallina, Luis
AB Evolutionary pressure has selected antibodies as key immune molecules acting against foreign pathogens. The development of monoclonal antibody technology has allowed their widespread use in research, real-time diagnosis and treatment of multiple diseases, including cancer. However, compared with hematologic malignancies, solid tumors have often proven to be relatively resistant to antibody-based therapies. In an attempt to improve the tumor-targeting efficacy of antibodies, new formats with modified, multivalent properties have been generated. Initially, these formats imitated the structure of native IgG, creating mostly monospecific, bivalent antibodies. Recently, novel trivalent antibodies have been developed to maximize tumor targeting capabilities through enhanced biodistribution and functional affinity. We review recent advances in the engineering of multivalent antibodies and further discuss their promise as agents for invivo diagnostics and therapy.
PB Cell Press
SN 0167-7799
YR 2010
FD 2010
LK https://hdl.handle.net/20.500.14352/92799
UL https://hdl.handle.net/20.500.14352/92799
LA eng
NO Cuesta AM, Sainz-Pastor N, Bonet J, Oliva B, Alvarez-Vallina L. Multivalent antibodies: when design surpasses evolution. Trends Biotechnol. 2010;28(7):355-362. doi:10.1016/j.tibtech.2010.03.007
NO Ministerio de Ciencia e Innovación (España)
NO Comunidad de Madrid
NO European Commission
DS Docta Complutense
RD 20 jul 2024